EDWARD GLAZEBROOK: Open Payments
NPI 1447919535 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,814 in 160 payments from 28 companies in 2025. Trend: 2023 $0 · 2024 $1,166 · 2025 $3,814
Food & beverage: $3,814
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 19 | $494 |
| Teva Pharmaceuticals USA, Inc. | 16 | $468 |
| ABBVIE INC. | 16 | $357 |
| AstraZeneca Pharmaceuticals LP | 12 | $301 |
| Otsuka America Pharmaceutical, Inc. | 13 | $245 |
| Gilead Sciences, Inc. | 9 | $243 |
| Neurocrine BioSciences, Inc. | 7 | $183 |
| Exact Sciences Corporation | 7 | $159 |
| Biogen, Inc. | 7 | $135 |
| Sumitomo Pharma America, Inc. | 6 | $134 |
Products named: AUSTEDO XR, MOUNJARO, VRAYLAR, REXULTI, INGREZZA, Cologuard Collection Kit, LEQEMBI, GEMTESA.
Industry payments across MA — which companies pay providers there.
